Outlook Therapeutics
OTLK
#8305
Rank
ยฃ0.11 B
Marketcap
ยฃ4.89
Share price
-5.25%
Change (1 day)
-32.84%
Change (1 year)

P/E ratio for Outlook Therapeutics (OTLK)

P/E ratio as of November 2024 (TTM): -24.9

According to Outlook Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -24.92. At the end of 2022 the company had a P/E ratio of -69.7.

P/E ratio history for Outlook Therapeutics from 2016 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-69.7-18.03%
2021-85.092.23%
2020-44.2708.85%
2019-5.47-51.07%
2018-11.2-32.54%
2017-16.6-21.31%
2016-21.0

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-9.72-60.99% Jersey
-1.25-95.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.2018-99.19%๐Ÿ‡บ๐Ÿ‡ธ USA
-2.69-89.19%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.